Bad blood: secrets and lies in a Silicon Valley startup
(Audio CD)
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When the author, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both the author and the newspaper were threatened with lawsuits. Undaunted, the paper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.--adapted from publisher's description.
Notes
Carreyrou, J., & Damron, W. (2018). Bad blood: secrets and lies in a Silicon Valley startup. Unabridged. New York, NY, Random House Audio.
Chicago / Turabian - Author Date Citation (style guide)Carreyrou, John and Will. Damron. 2018. Bad Blood: Secrets and Lies in a Silicon Valley Startup. New York, NY, Random House Audio.
Chicago / Turabian - Humanities Citation (style guide)Carreyrou, John and Will. Damron, Bad Blood: Secrets and Lies in a Silicon Valley Startup. New York, NY, Random House Audio, 2018.
MLA Citation (style guide)Carreyrou, John, and Will Damron. Bad Blood: Secrets and Lies in a Silicon Valley Startup. Unabridged. New York, NY, Random House Audio, 2018.
Record Information
Last Sierra Extract Time | Apr 22, 2024 11:20:17 PM |
---|---|
Last File Modification Time | Apr 22, 2024 11:20:23 PM |
Last Grouped Work Modification Time | Apr 26, 2024 01:37:11 AM |
MARC Record
LEADER | 03463cim 22006134a 4500 | ||
---|---|---|---|
001 | 1084446517 | ||
003 | OCoLC | ||
005 | 20190426024211.0 | ||
007 | sd fmngnnmmned | ||
008 | 190123s2018 nyunnnn z n eng d | ||
020 | |a 9780593105061 | ||
024 | 1 | |a 9780593105061 | |
028 | 4 | 2 | |a PRHA 7990|b Penguin Random House Audio |
035 | |a (OCoLC)1084446517|z (OCoLC)1084401242 | ||
037 | |a 60cjy8|b Blackstone Publishing | ||
037 | |a 40cjy8|b Blackstone Publishing | ||
040 | |a TOH|b eng|c TOH|d OCLCQ|d TEF|d BLACP|d GK8|d CoBoFLC | ||
043 | |a n-us--- | ||
050 | 4 | |a HD9995.H423|b U627 2018ab | |
082 | 0 | 4 | |a 338.7/681761|2 23 |
100 | 1 | |a Carreyrou, John,|e author. | |
245 | 1 | 0 | |a Bad blood|h [compact disc] :|b secrets and lies in a Silicon Valley startup /|c John Carreyrou. |
246 | 3 | 0 | |a Secrets and lies in a Silicon Valley startup |
250 | |a Unabridged. | ||
260 | |a New York, NY :|b Random House Audio,|c p2018. | ||
264 | 1 | |a New York, NY :|b Random House Audio,|c [2018] | |
264 | 4 | |c ℗2018 | |
300 | |a 9 audio discs (11 1/2 hr.) :|b digital ;|c 4 3/4 in. | ||
306 | |a 113000 | ||
336 | |a spoken word|b spw|2 rdacontent | ||
337 | |a audio|b s|2 rdamedia | ||
338 | |a audio disc|b sd|2 rdacarrier | ||
340 | |b 4 3/4 in. | ||
344 | |a digital|2 rdatr|0 http://rdaregistry.info/termList/typeRec/1002 | ||
344 | |b optical|2 rdarm|0 http://rdaregistry.info/termList/recMedium/1003 | ||
344 | |c 1.4 m/s | ||
344 | |g mono|2 rdapc|0 http://rdaregistry.info/termList/configPlayback/1001 | ||
344 | |h digital recording | ||
500 | |a Title from container. | ||
500 | |a Compact discs. | ||
511 | 1 | |a Read by Will Damron. | |
520 | |a In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When the author, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both the author and the newspaper were threatened with lawsuits. Undaunted, the paper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.--adapted from publisher's description. | ||
590 | |a BPL: some copies repackaged by Midwest Tape. | ||
600 | 1 | 0 | |a Holmes, Elizabeth,|d 1984- |
610 | 2 | 0 | |a Theranos (Firm)|x History. |
650 | 0 | |a Hematologic equipment industry|z United States. | |
650 | 0 | |a New business enterprises|x Corrupt practices|z United States|v Case studies. | |
650 | 0 | |a Securities fraud|z United States|v Case studies. | |
655 | 7 | |a Sound recording.|2 local | |
655 | 7 | |a Audiobooks.|2 lcgft | |
700 | 1 | |a Damron, Will. | |
907 | |a .b29007884|b bm | ||
945 | |y .i4433624x|i R0095558857|l bmbca|s -|h |u 21|x 2|w 0|v 10|t 19|z 190429|1 08-02-2023 18:10|o -|f D|a 338.7681761|b Holmes | ||
998 | |f -|e f |i eng|h bm |